Ranee Mehra, MD
- Request Appointment
- Clinical Locations
- Education, Training & Credentials
- Patient Stories
- Research Profile
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Chief, Head & Neck Hematology/Oncology
Associate Professor, Department of Hematology/Oncology
I came to Fox Chase Cancer Center in 2006 after completing my fellowship in medical oncology at Yale University. I chose Fox Chase because I was impressed by the Center's ability to provide compassionate care to its patients while striving to advance cancer treatment.
My fascination with emerging knowledge and new treatments in the field of oncology led me to become a medical oncologist. I find that cancer patients are a special group of people, and I enjoy being able to care for them.
In my practice, I specialize in lung cancer as well as cancers of the head and neck. Both are areas that can benefit from new treatment approaches. My research interests have included trials to study new treatments for ALK+ non-small cell lung cancer. Also, I am interested in the development of biomarkers to improve the treatment of head and neck cancers.
When it comes to treatment, I like to have a close communication with my patients throughout the course of their therapy. I believe each patient has his or her own individual needs that should be addressed in deciding on a treatment plan. Being diagnosed with cancer is a life-changing event, and I am sensitive as to how this affects both my patients and their families.
- Fellow, Medical Oncology, Yale University School of Medicine, New Haven, CT
- Resident, Internal Medicine, New York University Medical Center, New York, NY
- MD, New York University School of Medicine, New York, NY, 1999
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- National Comprehensive Cancer Network (NCCN)
- Small Cell Lung Cancer Guidelines Panel
- Alternate, US NCI Head and Neck Steering Committee
- American Society of Clinical Oncology
- ECOG Head and Neck Core Committee, Membership in the ADR Committee and ECOG Head and Neck Committee Toxicity Monitor
Honors & Awards
Fox Chase Cancer Center Leadership Forum Award, Fox Chase Cancer Center, 2012
2007 was a banner year for Connexus Technology and its owners, Lawrence James and Christopher Holland. Their company was awarded the Innovative Business of the Year Excellence Award by the Greater Philadelphia Chamber of Commerce. Lawrence was planning to carry the excitement into 2008 by proposing to his girlfriend, Tia McNair. However, a diagnosis of a rare cancer put a temporary stop to his plans. With his faith, and the doctors at Fox Chase Cancer Center on his side, Lawrence put up a strong fight and won his battle with cancer.
In 2009, John Reeves took a bad fall. "That's when it all started," he recalled. At the age of 78, John didn't recover as quickly as he expected. A former high school football star and self-titled #1 concrete man in Philadelphia, John is a strong guy. He sought medical attention, and during a routine x-ray, doctors saw something suspicious.
A former smoker for 35 years, John kicked the habit in 1995. "I really didn't think about getting lung cancer anymore," he admitted.
Beth Valenti always knew smoking was not a good idea, but like many people, she did it anyway. She was young and never really thought about lung cancer. But after losing her mom to cancer in 1996, Beth quit the habit cold turkey. Almost 12 years later, in March 2008, she went to the doctor complaining of pain in her arm. A series of shoulder x-rays revealed a mass on her lung. According to Beth, her doctors advised her to "go home, get your things in order and plan your funeral." She was 41 at the time.
Paul Reitano was in very good health prior to his cancer diagnosis in 2012. An avid participant of martial arts and working-out, he is fortunate to have two successful careers: his day job is working as an engineer’s assistant for the Delaware Valley Regional Planning Commission, and his second career is as a photographer of both of corporate and social events. But his world turned upside down in October, 2012, when Paul felt a lump in the left side of his neck.
On May 6, 2014, B. Mark Wilson of Smyrna, Del., made a chance visit to Fox Chase Cancer Center. The 51-year-old came to accompany his father, George, for a follow-up visit. The elder Wilson had been treated for kidney cancer two years earlier. Mark, who had just been diagnosed with stage IV throat cancer, was just days away from his own surgery, and brought along his medical paperwork. “I was hoping for a second opinion,” he admitted. “Little did I know Fox Chase has a Rapid Access Program, which meant I could be seen immediately.
My clinical and research interests focus on head and neck cancers, including thyroid and salivary gland malignancies and thoracic malignancies. I am a clinical investigator with an interest in developmental therapeutics. I also focus on evaluating biomarkers as they relate to head and neck tumor characteristics and prognosis, with the goal of eventually being able to optimize care based on a tumor’s biomarker profile. I am interested in incorporating novel agents in the management of head and neck and thoracic malignancies and have been either the principal or co-Investigator for clinical trials utilizing targeted therapies and immune checkpoint inhibitors. I am Co-PI of the ALK arm of the NCI Match clinical trial. In addition, I am an active member of the ECOG Head and Neck Committee.
Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiski I, Burtness BA, Golemis EA, Mehra R. Phospho-T356RB1 predicts survival in HPV-Negative Squamous Cell Carcinoma of the Head and Neck. Oncotarget. Aug. 7, 2015. PubMed
Galloway T, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015 Jan 8. pii: clincanres.2820.2014. PubMed
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder DB, Ridge JA. Increasing time to treatment initiation for head and neck cancer: An analysis of the National Cancer Database. Cancer. 2014 Dec 9. doi: 10.1002/cncr.29191. PubMed
Egloff AM, Lee JW, Langer C, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang DH, Mehra R, Ridge JA, Patel UA, Burtness B, Forastiere AA. Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clin Cancer Res. 2014 Aug 8 (Epub). PubMed
Cohen EW, Karrison T, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein B, Agulnik M, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor V, Haraf DJ, Vokes EE. Phase III Randomized Trial of Induction Chemotherapy in Patients with N2/N3 Locally Advanced Head and Neck Cancer. J Clin Oncol, 2014, 32:2735-2743. PubMed
Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Annals of Oncology. 2014 Jul; 25(7):1410-6. PubMed
Shaw AT, Kim DW, Mehra R, Tan DSW, Felip E, Chow L, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu L, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer. N Engl J Med 2014; 370:1189-1197.
Ragin C, Obikoya-Malomo M; Kim S, Chen Z, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso N, Carpagnano G, Ciotti M, Dosaka-Akita H, Fukayama M, Goto A, Spandidos DA, Gorgoulis V, Heideman D, van Boerdonk R, Hiroshima K, Iwakawa R, Kastrinakis N, Kinoshita I, Akiba S, Landi M, Liu HE, Wang J-L, Mehra, R, Khuri F, Lim W-T, Owonikoko T, Ramalingam S, Sarchianaki E, Syrjanen K, Tsao M, Sykes J, Hee SW, Yokota J, Zaravinos A, Taioli E. HPV-Associated Lung Cancers: an International Pooled Analysis. Carcinogenesis. 2014 Feb 26. PubMed
Mehra R, Zhu F, Yang D, Cai K, Weaver J, Singh MK, Nikonova A, Golemis EA, Flieder D, Cooper H, Lango M, Ridge JA, Burtness BA. Quantification of excision repair cross complementing group 1 (ERCC1) and survival in p16-negative squamous cell head and neck cancer. Clin Cancer Res December 1, 2013 19; 6633. PubMed
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. JNCCN. 2012 Nov 1;10(11):1391-1398. PubMed
Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns. Head Neck. 2012 Feb 2. doi: 10.1002/hed.22929. [Epub ahead of print]. PubMed
Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy B, Gilbert J, Mehra R, Moore D, Sheikh A, Hoskins JM, Hayward MC, Zhao N, Weck KE, Cohen RE, Cohen EE. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) with or without follicular elements. Clin Cancer Res. 2012 Jan 12. [Epub ahead of print]. PubMed
Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center Experience. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2011 Oct;33(10):1433-40. PubMed
Kurzrock R, Sherman S, Ball D, Forastiere A, Cohen RB, Mehra R,, Pfister D, Cohen EW, Janisch L, Nauling F, Hong D, Ng CYe L, Gagel R, Frye J, Müller zt, Ratain MJ and Salgia R. Activity of XL184, an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. Epub 2011 May 23. PubMed
Dr. Mehra on My NCBI